poisar

Stocks · News reference

Wedbush Raises Price Target on Benitec Biopharma to $20 From $17

Fiscal.ai

Wedbush Securities has increased its price target for Benitec Biopharma Inc. from $17 to $20 while maintaining an 'Outperform' rating.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Benitec Biopharma Inc. (BNTC)

    Filed: 2026-11-13 AccNo: 0001193125-26-459339 Size: 378 KB Item 2.02: Results of Operations and Financial Condition Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits